Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

June 25, 2025

Study Completion Date

June 25, 2025

Conditions

Solid Tumor

Interventions

DRUG

BBI-825

Oral RNR inhibitor

Trial Locations (5)

Memorial Sloan Kettering Cancer Center, New York

START Midwest, Grand Rapids

NEXT Oncology, Irving

NEXT Oncology, San Antonio

Sarcoma Oncology Research Center, Santa Monica